Cargando…

The Role of Patient-Derived Organoids in Triple-Negative Breast Cancer Drug Screening

Triple-negative breast cancer (TNBC) is one of the most aggressive breast cancer subtypes, with a grave prognosis and few effective treatment options. Organoids represent revolutionary three-dimensional cell culture models, derived from stem or differentiated cells and preserving the capacity to dif...

Descripción completa

Detalles Bibliográficos
Autores principales:	Psilopatis, Iason, Mantzari, Amalia, Vrettou, Kleio, Theocharis, Stamatios
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10045189/ https://www.ncbi.nlm.nih.gov/pubmed/36979752 http://dx.doi.org/10.3390/biomedicines11030773

Ejemplares similares

Patient-Derived Organoids: The Beginning of a New Era in Ovarian Cancer Disease Modeling and Drug Sensitivity Testing
por: Psilopatis, Iason, et al.
Publicado: (2022)

The Role of Bitter Melon in Breast and Gynecological Cancer Prevention and Therapy
por: Psilopatis, Iason, et al.
Publicado: (2023)

Organoids: A New Chapter in Sarcoma Diagnosis and Treatment
por: Psilopatis, Iason, et al.
Publicado: (2022)

The Role of Peroxisome Proliferator-Activated Receptors in Endometrial Cancer
por: Psilopatis, Iason, et al.
Publicado: (2023)

The Role of MicroRNAs in Uterine Leiomyosarcoma Diagnosis and Treatment
por: Psilopatis, Iason, et al.
Publicado: (2023)

The Role of Peroxisome Proliferator-Activated Receptors in Preeclampsia
por: Psilopatis, Iason, et al.
Publicado: (2023)

EPH/Ephrin-Targeting Treatment in Breast Cancer: A New Chapter in Breast Cancer Therapy
por: Psilopatis, Iason, et al.
Publicado: (2022)

The Role of Peroxisome Proliferator-Activated Receptors in Polycystic Ovary Syndrome
por: Psilopatis, Iason, et al.
Publicado: (2023)

The Impact of Histone Modifications in Endometriosis Highlights New Therapeutic Opportunities
por: Psilopatis, Iason, et al.
Publicado: (2023)

The EPH/Ephrin System in Gynecological Cancers: Focusing on the Roots of Carcinogenesis for Better Patient Management
por: Psilopatis, Iason, et al.
Publicado: (2022)

Thymic Epithelial Neoplasms: Focusing on the Epigenetic Alterations
por: Psilopatis, Iason, et al.
Publicado: (2022)

May EPH/Ephrin Targeting Revolutionize Lung Cancer Treatment?
por: Psilopatis, Iason, et al.
Publicado: (2022)

Histone Deacetylase Inhibitors: A Promising Therapeutic Alternative for Endometrial Carcinoma
por: Psilopatis, Iason, et al.
Publicado: (2021)

The Role of Hyperthermic Intraperitoneal Chemotherapy in Uterine Cancer Therapy
por: Psilopatis, Iason, et al.
Publicado: (2023)

Ovarian Torsion in Polycystic Ovary Syndrome: A Potential Threat?
por: Psilopatis, Iason, et al.
Publicado: (2023)

The Emerging Role of Histone Deacetylase Inhibitors in Cervical Cancer Therapy
por: Psilopatis, Iason, et al.
Publicado: (2023)

FDA-Approved Monoclonal Antibodies for Unresectable Hepatocellular Carcinoma: What Do We Know So Far?
por: Psilopatis, Iason, et al.
Publicado: (2023)

EPHA2, EPHA4, and EPHA7 Expression in Triple-Negative Breast Cancer
por: Nikas, Ilias, et al.
Publicado: (2022)

The TRIPLEX study: use of patient-derived tumor organoids as an innovative tool for precision medicine in triple-negative breast cancer
por: Divoux, Jordane, et al.
Publicado: (2023)

Patient-Derived Organoids in Precision Medicine: Drug Screening, Organoid-on-a-Chip and Living Organoid Biobank
por: Zhou, Zilong, et al.
Publicado: (2021)

Drug Repurposing for Triple-Negative Breast Cancer
por: Ávalos-Moreno, Marta, et al.
Publicado: (2020)

Patient‐derived organoids for personalized gallbladder cancer modelling and drug screening
por: Yuan, Bo, et al.
Publicado: (2022)

Human Lung Adenocarcinoma-Derived Organoid Models for Drug Screening
por: Li, Zhichao, et al.
Publicado: (2020)

Role of SMC1 in Overcoming Drug Resistance in Triple Negative Breast Cancer
por: Yadav, Sushma, et al.
Publicado: (2013)

Repurposing of drugs for triple negative breast cancer: an overview
por: Spini, Andrea, et al.
Publicado: (2020)

Investigational Drug Treatments for Triple-Negative Breast Cancer
por: Damaskos, Christos, et al.
Publicado: (2021)

A high-throughput drug screen reveals means to differentiate triple-negative breast cancer
por: Vulin, Milica, et al.
Publicado: (2022)

Prognostic role of derived neutrophil-to-lymphocyte ratio in surgical triple-negative breast cancer
por: Ren, Kuojun, et al.
Publicado: (2018)

High-throughput drug screening of fine-needle aspiration-derived cancer organoids
por: Bergdorf, Kensey, et al.
Publicado: (2020)

Patient-derived organoids as a platform for drug screening in metastatic colorectal cancer
por: He, Xingfeng, et al.
Publicado: (2023)

SOX11 and Epithelial-Mesenchymal Transition in Metastatic Serous Ovarian Cancer
por: Psilopatis, Iason, et al.
Publicado: (2023)

Role of BET Inhibitors in Triple Negative Breast Cancers
por: Khandekar, Durga, et al.
Publicado: (2020)

The Roles of DNA Demethylases in Triple-Negative Breast Cancer
por: Panjarian, Shoghag, et al.
Publicado: (2021)

Combinatorial drug screening of mammary cells with induced mesenchymal transformation to identify drug combinations for triple-negative breast cancer
por: Colavito, Sierra A., et al.
Publicado: (2019)

Approach to the Triple Negative Breast Cancer in New Drugs Area
por: Mirzania, Mehrzad
Publicado: (2016)

Novel antibody–drug conjugates for triple negative breast cancer
por: Nagayama, Aiko, et al.
Publicado: (2020)

Emerging Therapeutic Drugs in Metastatic Triple-Negative Breast Cancer
por: Cipriano, Élia, et al.
Publicado: (2021)

Empowering Clinical Decision Making in Oligometastatic Colorectal Cancer: The Potential Role of Drug Screening of Patient-Derived Organoids
por: Mauri, Gianluca, et al.
Publicado: (2021)

Role of betulinic acid derivative SH-479 in triple negative breast cancer and bone microenvironment
por: Tang, Liang, et al.
Publicado: (2021)

Triple-Negative Breast Cancer
por: Chu, Quyen D., et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_onou6bfg617jh7s5066ljecl71